Alumis Inc. Common Stock (ALMS) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in South San Francisco, CA, United States. Der aktuelle CEO ist Martin Babler.
ALMS hat IPO-Datum 2021-02-22, 168 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $2.82B.
Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative medicines for autoimmune and neuroinflammatory disorders. The company's lead candidate, ESK-001, is an allosteric tyrosine kinase 2 (TYK2) inhibitor in development for plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis. Additionally, Alumis is advancing A-005, a brain-penetrant TYK2 inhibitor designed to treat neuroinflammatory and neurodegenerative diseases. Founded in 2021 and formerly known as Esker Therapeutics, the company rebranded to Alumis Inc. in January 2022 and is headquartered in South San Francisco, California.
